The UK and US have forged a major trade agreement that will ensure no tariffs on UK pharmaceutical shipments going into the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This move guarantees that duties on these crucial products will be held at zero for a duration of the next three years.
This development comes after recent statements to hike duties on patented pharmaceutical products, with increases discussed reaching one hundred percent.
"This agreement with the UK reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. pharmaceutical trade," an announcement said.
Economic Significance
Medicines represent one of the the United Kingdom's most significant exports to the America, which is by far the largest buyer for leading British pharmaceutical firms.
Export figures show that in the 12 months to the end of September, the UK sold drugs totaling over eleven billion pounds to the US. This amount made up 17.4% of all goods exports in that period.
"This agreement safeguards employment, increases funding and sets the stage for the UK to establish itself as a global hub for medical research," a government official remarked.
Detailed UK Commitments
The deal entails several specific commitments from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to raise overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. Previously, refunds were more than 20%.
Recent Tensions
This agreement comes amid a long-running dispute between the drug companies and the ministers over spending levels and regulatory access.
These tensions were exacerbated by claims that American customers were charged several times more for the same drugs than patients in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been paused or abandoned, while substantial expansions have been announced toward US facilities.
One official stated that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.
